Personalized immunotherapy for lung cancer under the guidance of pathology

LI Yuan

doi:10.19401/j.cnki.1007-3639.2020.10.007

您当前的位置：

首页 >

文章列表页 >

Personalized immunotherapy for lung cancer under the guidance of pathology

更新时间：2026-01-27

- Personalized immunotherapy for lung cancer under the guidance of pathology
- China Oncology Vol. 30, Issue 10, Pages: 770-776(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.10.007
  CLC：
- Published Online：12 November 2020，
  
  Published：12 November 2020
- 稿件说明：
移动端阅览
李　媛. 病理学指导下的非小细胞肺癌个体化免疫治疗[J]. 中国癌症杂志, 2020, 30(10): 770-776.

LI Yuan. Personalized immunotherapy for lung cancer under the guidance of pathology[J]. China Oncology, 2020, 30(10): 770-776.
李　媛. 病理学指导下的非小细胞肺癌个体化免疫治疗[J]. 中国癌症杂志, 2020, 30(10): 770-776. DOI： 10.19401/j.cnki.1007-3639.2020.10.007.

LI Yuan. Personalized immunotherapy for lung cancer under the guidance of pathology[J]. China Oncology, 2020, 30(10): 770-776. DOI： 10.19401/j.cnki.1007-3639.2020.10.007.

摘要

在肺癌个体化免疫治疗时代，如何有效地筛选程序性死亡［蛋白］-1（programmed death-1，PD-1）/程序性死亡［蛋白］配体-1（programmed death ligand-1，PD-L1）免疫检查点抑制剂潜在获益人群成为免疫治疗时代面临的新挑战。病理科医师通过免疫组织化学检测非小细胞肺癌（non-small cell lung cancer，NSCLC）组织中PD-L1的表达水平，可为预测PD-1/PD-L1免疫检查点抑制剂治疗晚期NSCLC的疗效和预后提供准确可靠的依据。此外，病理科医师可通过传统病理学方法观察主要病理学缓解（major pathological response，MPR）程度，进一步评价早中期肺癌免疫新辅助治疗的效果。对目前病理学诊断指导下的NSCLC个体化免疫治疗的进展以及未来的发展方向进行综述。

Abstract

In the era of personalized immunotherapy for lung cancer

how to effectively screen potential beneficiaries of programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint inhibitors has become a new challenge. The expression levels of PD-L1 in non-small cell lung cancer (NSCLC) can be detected by immunohistochemistry

which provides accurate and reliable information for predicting the efficacy of PD-1/PD-L1 immunotherapy and prognosis in advanced NSCLC. In addition

traditional pathology can be used to observe major pathological response (MPR) to further evaluate the efficacy of neoadjuvant immunotherapy for early/middle-stage NSCLC. This review summarized the current progress and future development of personalized immunotherapy for NSCLC under the guidance of pathology.

关键词

Keywords

references

Views

2572

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Immune microenvironment for liver metastasis of non-small cell lung cancer and future intervention strategies

BIMcombined with Scribble predicts treatment effect from chemotherapy in advanced non-small cell lung cancer

Expression of prospero-related homeobox protein 1 and its significance in non-small cell lung cancer

Feasibility study of immunohistochemistry for liquid-based cytology in pleural exfoliation examination

Microcystic meningioma: a clinicopathologic analysis of two cases and literature review

Related Author

SU Chunxia

ZHOU Juan

FANG Yujia

ZHANG Xin

HOU Yingyong

JIANG Dongxian

YAO Jiamei

ZHANG Longfu

Related Institution

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

上海市徐汇区中心医院呼吸科

复旦大学附属中山医院呼吸科

复旦大学附属中山医院病理科

淄博市第一医院心胸外科

AI问答

⁰